This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Academic Highlights

Clinical Insights Into Pharmacogenetics and Schizophrenia, Part 1

John M. Kane, MD; Roy H. Perlis, MD, PhD; and Anil K. Malhotra, MD

Published: March 14, 2008

Article Abstract

Click to enlarge page

Schizophrenia is a heterogeneous disorder in terms of course and treatment response. The field of pharmacogenetics, which seeks to reveal how genetic factors affect patients’ response to drugs, holds promise to help clinicians develop a better understanding of antipsychotic therapy,1 such as which patients might respond better or worse to specific agents or treatment in general or which patients might be at particular risk for serious adverse effects.

What do practicing psychiatrists need to know about using genetic tests?


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 69

Quick Links: Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...